Claims for Patent: 9,283,215

Summary for Patent: 9,283,215

Title:	Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies
Abstract:	Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	14/201,069
Patent Claims:	1. A method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma (a) about 1 to about 5 mg per day of a compound having the formula: ##STR00009## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and (b) a therapeutically effective amount of an antibody, wherein the compound is administered in one or more cycles, each of which comprises administering the compound for a period of time followed by a period of rest, wherein the multiple myeloma is relapsed, refractory, or relapsed and refractory. 2. The method of claim 1, wherein the compound is ##STR00010## and is not a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 3. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt. 4. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate. 5. The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer. 6. The method of claim 1, wherein the antibody is a monoclonal or polyclonal antibody. 7. The method of claim 6, wherein the antibody is a monoclonal antibody. 8. The method of claim 6, wherein the antibody is trastuzumab, rituximab, cetuximab, bevacizumab, pertuzumab, tositumomab, infliximab, edrecolomab or G250, or a combination thereof. 9. The method of claim 6, wherein the antibody is an anti-TNF-.alpha. antibody. 10. The method of claim 1, wherein the compound is administered concurrently with, prior to, or following administration of the antibody. 11. The method of claim 1, wherein the compound is administered in an amount of about 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg per day. 12. The method of claim 1, wherein the compound is administered orally. 13. The method of claim 12, wherein the compound is administered in the form of a capsule or tablet. 14. The method of claim 13, wherein the compound is administered orally in a capsule in an amount of about 1 mg, 2 mg, 3 mg, 4 mg or 5 mg. 15. The method of claim 13 wherein the capsule comprises the compound, mannitol and pre-gelatinized starch. 16. The method of claim 1, wherein the compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 17. The method of claim 1, wherein the compound is administered in an amount of about 4 mg per day for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 18. The method of claim 1, wherein the compound is administered until disease progression or unacceptable toxicity. 19. The method of claim 1, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount from about 1 to about 1000 mg. 20. The method of claim 19, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount from about 5 to about 500 mg. 21. The method of claim 19, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount from about 10 to about 350 mg. 22. The method of claim 19, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount from about 50 to about 200 mg. 23. The method of claim 1, further comprising administering a therapeutically effective amount of an additional active agent. 24. The method of claim 23, wherein the additional therapeutic agent is dexamethasone, melphalan, prednisone, or a combination thereof. 25. The method of claim 24, wherein the dexamethasone is administered in an amount of about 40 mg per day. 26. The method of claim 24, wherein the dexamethasone is orally administered once daily on days 1, 8, 15 and 22 of a 28 day cycle. 27. The method of claim 24, wherein the dexamethasone is orally administered once a week of a 28 day cycle. 28. The method of claim 1, further comprising administering radiation therapy, hormonal therapy, or immunotherapy.

Details for Patent 9,283,215

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2022-05-17
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2022-05-17
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2022-05-17
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2022-05-17
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2022-05-17
Glaxosmithkline Llc	BEXXAR	tositumomab and iodine i-131 tositumomab	Injection	125011	06/27/2003		2022-05-17
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2022-05-17